CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-06 | Wu Xiaobin President and COO | Sale | −400 | $250.74 | $100K | 1,534 |
| 2025-06-06 | Wu Xiaobin President and COO | Sale | −500 | $251.85 | $126K | 1,034 |
| 2025-06-06 | Wu Xiaobin President and COO | Sale | −400 | $253.50 | $101K | 634 |
| 2025-06-06 | Wu Xiaobin President and COO | Sale | −400 | $255.31 | $102K | 234 |
| 2025-06-06 | Wu Xiaobin President and COO | Sale | −234 | $255.77 | $60K | 0 |
| 2025-06-06 | OYLER JOHN Chief Executive Officer | Sale | −1,400 | $250.84 | $351K | 3,727 |
| 2025-06-06 | OYLER JOHN Chief Executive Officer | Sale | −1,400 | $251.88 | $353K | 2,327 |
| 2025-06-06 | OYLER JOHN Chief Executive Officer | Sale | −1,000 | $253.49 | $253K | 1,327 |
| 2025-06-06 | OYLER JOHN Chief Executive Officer | Sale | −927 | $254.97 | $236K | 400 |
| 2025-06-06 | OYLER JOHN Chief Executive Officer | Sale | −400 | $255.74 | $102K | 0 |
| 2025-05-21 | Yi Qingqing Director | Grant or award | +10,985 | 56,940 | ||
| 2025-05-21 | Yi Qingqing Director | Grant or award · Share Option (Right to Buy) | +22,750 | 22,750 | ||
| 2025-05-21 | Sharp Shalini Director | Grant or award | +10,985 | 19,136 | ||
| 2025-05-21 | Sharp Shalini Director | Grant or award · Share Option (Right to Buy) | +22,750 | 22,750 | ||
| 2025-05-21 | BRANDICOURT OLIVIER Director | Grant or award | +10,985 | 27,326 | ||
| 2025-05-21 | BRANDICOURT OLIVIER Director | Grant or award · Share Option (Right to Buy) | +22,750 | 22,750 | ||
| 2025-05-21 | Riva Alessandro Director | Grant or award | +10,985 | 56,940 | ||
| 2025-05-21 | Riva Alessandro Director | Grant or award · Share Option (Right to Buy) | +22,750 | 22,750 | ||
| 2025-05-21 | Dugan Margaret Director | Grant or award | +10,985 | 56,940 | ||
| 2025-05-21 | Dugan Margaret Director | Grant or award · Share Option (Right to Buy) | +22,750 | 22,750 |
Page 25 of 71 · 1,406 trades